Abstract
Overview
Introduction
Vaccines have re-emerged as successful revenue generators for Big Pharma, with
adults and the elderly now increasingly coming into focus as the next big
opportunity in this sector. An aging population, rising disease awareness and
new technologies to overcome the scientific hurdles linked to the weakened
immune response in the elderly are all contributing factors.
Scope
- Assessment of pneumococcal and zoster disease incidence, in-depth analysis
of existing vaccines and key pipeline compounds
- Review of current and expected future immunization guidelines as well as
existing and forecast immunization rates
- 10-year sales forecast on a population basis for Zostavax, Prevnar 13 and
Pneumovax-23
- Overview of current booster vaccine recommendations and commercial
landscape with analysis of future market drivers
Highlights
Following the great success of Wyeth' s heptavalent pneumococcal vaccine
Prevnar in the infant sector, Datamonitor believes that Prevnar 13 could
achieve blockbuster status in adults and elderly alone, if a superior efficacy
compared to Pneumovax 23 is confirmed in ongoing clinical trials.
Merck & Co' s Zostavax is the only available vaccine for the prevention of
shingles and will continue to enjoy a monopoly in this promising market due to
a lack of pipeline competitors. Datamonitor predicts peak sales between $1.5
and $2 billion.
Sanofi Pasteur and GSK are the leading players in the booster vaccines market.
Overall, Datamonitor predicts significant growth potential in this sector,
based on both geographic expansion of existing booster indications as well as
the potential introduction of additional booster vaccinations for new
indications.
Reasons to Purchase
- Size the available market opportunities and identify the unmet medical
needs when immunizing an elderly patient population
- Gain insight into key opinion leaders' thinking on vaccines for the elderly
- Understand and identify the key challenges to achieving a better
penetration of the next big opportunity in the vaccine area